Form 4: Dyadic International Executive Granted Stock Options

Joseph P. Hazelton, Chief Business Officer of Dyadic International, received stock options as part of his appointment.

Summary

• Joseph P. Hazelton, Chief Business Officer of Dyadic International, was granted stock options on April 11, 2024.
• The stock option is for 20,000 shares of Dyadic International's common stock.
• The exercise price of the stock option is $1.84.
• The stock option vests in four equal installments beginning on April 11, 2025.
• The stock option expires on April 11, 2034.

Sentiment

Score: 7

Explanation: The granting of stock options is a neutral to slightly positive event, indicating confidence in the executive and the company's future prospects. It's a standard practice, so the impact is moderate.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the biotechnology industry to attract and retain talent.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for stock option grants in similar companies.

Stakeholder Impact

• Shareholders may view the granting of stock options as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates